MoonLake Immunotherapeutics (MLTX) Stock Analysis & Investment Frameworks
MoonLake Immunotherapeutics (MLTX) stock analysis on Invetso. Review MoonLake Immunotherapeutics’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
MoonLake Immunotherapeutics Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CH
MoonLake Immunotherapeutics Key Financial Metrics
- Market Cap: $919.15M
- Revenue: $N/A
- ROE: -79.95%
- ROIC: -57.27%
- Dividend Yield: N/A
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.